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The Memokath-051 Stent for the Treatment of Ureteric
Obstruction: A NICE Medical Technology Guidance
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Abstract Memokath-051 is a thermo-expandable, nickel-
titanium alloy spiral stent used to treat ureteric obstruction
resulting from malignant or benign strictures. The National
Institute for Health and Care Excellence (NICE) selected
Memokath-051 for evaluation. The company, PNN Medi-
cal, claimed Memokath-051 has clinical superiority and
cost savings compared with double-J stents. It identified
five studies reporting clinical evidence on Memokath-051
and constructed a de novo cost model comparing Memo-
kath-051 to double-J stents. Results indicated that Memo-
kath-051 generated cost savings of £4156 per patient over
2.5 years. The External Assessment Centre (EAC) cri-
tiqued the company’s submission and completed substan-
tial additional work. Sixteen studies were identified
assessing Memokath-051 and all listed comparators in the
scope (double-J stents, reconstructive surgery and metallic
and alloy stents) except nephrostomy. Similar success rates
were reported for Memokath-051 compared with double-J
and Resonance stents and worse outcomes compared with
other options with evidence available. The EAC updated
the company’s cost model structure and modified several
inputs. The EAC’s model estimated that Memokath-051
generated savings of at least £1619 per patient over 5 years
compared with double-J stents, was cost neutral compared
with other metallic stents and was cost saving compared
with surgery up to month 55. Overall, Memokath-051 is
likely to be cost saving in patients not indicated for
reconstructive surgery and those expected to require a
ureteral stent for at least 30 months. The Medical Tech-
nologies Advisory Committee (MTAC) reviewed the evi-
dence and supported the case for adoption, issuing partially
supportive recommendations published after public con-
sultation as Medical Technologies Guidance 35.
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Key Points for Decision Makers
The case for adopting Memokath-051 compared with
double-J stents for treating ureteric obstruction is
partially supported by evidence.
The evidence is limited but suggests that in selected
patients, Memokath-051 is effective at relieving
ureteric obstruction and improving quality of life.
When inserted by clinicians trained in using
Memokath-051 specifically and in appropriate
patients, Memokath-051 is associated with
equivalent success rates and a better patient
experience compared with double-J stents.
The cost consequences of adopting Memokath-051
are uncertain. However, when used in appropriate
patients and by clinicians trained in its use, potential
cost savings resulting from fewer repeat procedures
may arise with Memokath-051.
The key challenges of the assessment resulted from
the poor quality and quantity of available evidence
and therefore uncertainty in conclusions.
1 Introduction
Novel and innovative medical devices and diagnostics can
be evaluated to support evidence-based medical technolo-
gies guidance produced by the National Institute for Health
and Care Excellence (NICE). Where appropriate, this can
encourage adoption of the medical devices and diagnostics
within the National Health Service (NHS) in England.
Companies may notify technologies to NICE. NICE also
identifies topics from a variety of sources, including NHS
England and horizon scanning organisations. Selecting
which technologies to evaluate uses criteria including the
potential to offer clinical benefits to patients and the NHS,
and/or to reduce costs, compared with standard care. The
Medical Technologies Advisory Committee (MTAC)
develops guidance following independent assessment of
the clinical and economic evidence submitted by the
company, conducted by an External Assessment Centre
(EAC), and after a public consultation period. The Medical
Technologies Evaluation Programme (MTEP) methodol-
ogy is described in detail by Campbell and Campbell [1].
In February 2018, NICE issued final guidance on Mem-
okath-051 for treating ureteral obstruction. Memokath-051
is a single-use, thermo-expandable, nickel-titanium alloy
spiral stent [2]. The EAC critiquing the evidence was the
Newcastle upon Tyne Hospitals NHS Foundation Trust and
York Health Economics Consortium partnership. Clinical
experts, identified using NICE’s published processes [3],
provided advice to the EAC and MTAC.
This article is one of a series of Medical Technology
Guidance summaries published by this journal. It includes
an overview of the clinical and economic benefits of
Memokath-051 as reported in the company’s submission,
the EAC’s assessment report [4] and the subsequent
development of the NICE guidance [5]. The NICE website
provides full documentation of the process, supporting
evidence and the final guidance [5].
2 Background to the Indication and Devices
The ureter is a narrow muscular duct that urine flows
through from a kidney to the bladder [6]. A ureteric
stricture is characterised by a narrowing of the ureter and
can have malignant or benign causes. When the ureter is
obstructed, the normal flow of urine from the kidney to the
bladder is disrupted, which can lead to complications
associated with the kidney and urinary tract. Irrespective of
the cause of the stricture, it is necessary to relieve the
obstruction in the ureter [6]. Memokath-051 is inserted into
the ureter. The thermo-sensitive ‘shape memory’ of the
stent softens it in the pre-insertion state, but once inserted
and heated, the distal end of the stent (or both ends if a
double cone design) returns to a preformed cone shape,
which anchors the stent into position within the ureter. The
stent then keeps the ureter open [7, 8].
The assessment of Memokath-051 was conducted for the
indications of benign or malignant strictures in line with the
scope produced by NICE [9]. The patient population
receiving treatment for ureteric stricture is heterogeneous
(i.e. differing degrees of underlying disease severity, patient
condition and life expectancy). Clinical experts advised that
when a patient has a malignant stricture, the type of cancer
determines life expectancy. Therefore, the functional life-
time of the stent depends on the life expectancy of the patient
rather than the degree of the stricture. The life expectancy of
patients with malignant ureteral obstruction is poorly
reported in the literature, but median estimates of less than
1 year [10] and 3.7–15.3 months have been reported [11].
The life expectancy of patients with benign strictures would
not usually be limited by the aetiology of the stricture, but
rather is expected to alignwith that for amatched group in the
general population.
In the NHS, people with ureteric obstruction are gen-
erally treated in secondary care. Stents can be inserted into
the ureter either by an antegrade or retrograde procedure
where the stent is inserted via the bladder or via the kidney,
respectively. Clinical experts advised that the method
selected is based on ureteric anatomy, reconstruction and
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tolerability of the bladder component stent. Antegrade
insertion is used if retrograde access fails. The procedure is
conducted by a urologist or radiologist, typically in an
operating theatre under general anaesthetic, but can be
done under local anaesthetic. Following the stenting pro-
cedure, patients typically attend three follow-up appoint-
ments in the year following insertion. There are multiple
surgical options available to patients with ureteric stric-
tures: ureteric re-implantation into the bladder, balloon
dilation, laser endopyelotomy and extra-anatomical bypass.
Depending on the type of reconstructive surgery, the pro-
cedure can be conducted as either open or laparoscopic
surgery. An expert advised that as part of reconstructive
surgery, patients have a double-J stent inserted. This is
removed a few weeks after surgery once healing has
occurred.
Data from the Hospital Episode Statistics (HES) data-
base for England show that in 2014–2015 there were 7674
retrograde insertions, 2733 retrograde removals of ureteric
stents, 80 cases of percutaneous insertions (i.e. antegrade
insertions) and 22 replacements of ureteric metallic stents
[12]. These data are for all available stent types, with no
information available on the type of stent used or the rea-
son for stenting.
Stenting using devices such as Memokath-051 is inten-
ded to offer immediate relief of the patient’s symptoms.
The principle purpose of reconstructive surgery is to
remove the obstruction. Clinical experts advised that
patients who can tolerate surgery, mainly those with benign
strictures, should be referred to a tertiary centre. A claimed
benefit of the Memokath-051 stent over comparator stents
is that it requires less frequent replacement. Clinical
experts noted that double-J stents can remain in situ for up
to 6 months before they must be removed or replaced. For
metallic stents, the time they can remain in situ varies from
12 months for Resonance [13] to 18 months for UVENTA
[14] and 3 years for Allium [15]. Some studies report
Memokath-051 indwelling times of up to 4 years [16, 17].
The scope [9] defined the relevant comparators to
Memokath-051 as other stent types (double-J stents and
alloy or metallic stents), nephrostomy and reconstructive
surgery. The decision problem addressed by the company
and EAC and how these compare to the scope is now
described.
3 Decision Problem (Scope)
3.1 Population
The population described in the scope [9] was people with
ureteric obstruction as a result of malignant or benign
strictures. The company did not include evidence that
included patients with only malignant or only benign
strictures, but the EAC identified and included studies that
made reference to malignant stricture, benign stricture or
both. Subgroups were also specified, including people unfit
for surgery, those with a malignant stricture or a benign
stricture, either antegrade or retrograde insertion, and the
procedure being performed by an interventional radiologist
or urologist. Subgroup analysis was not conducted by the
company. The EAC identified limited clinical evidence on
the subgroup of benign versus malignant stricture, but there
was a paucity of information to inform other subgroup
analyses.
3.2 Intervention
The intervention specified in the scope and matched by the
company’s submission was ‘Memokath-051’ [9].
3.3 Comparator
Four comparators were specified in the scope: double-J
stents, nephrostomy, reconstructive surgery and metallic
and alloy stents [9]. In the NHS, there are numerous
varieties of double-J stents available [18]. This analysis is
not specific to a particular double-J stent. The EAC iden-
tified three metallic or alloy stents available in the NHS,
namely, UVENTA, Allium and Resonance. Clinical
experts advised that the following surgical options are
available to patients with ureteric strictures: ureteric re-
implantation into the bladder, balloon dilation, laser
endopyelotomy, extra-anatomical bypass and ileal ureter
replacement (IUR). The company compared Memokath-
051 with double-J stents only. The EAC identified evidence
for UVENTA, Allium, Resonance, double-J and IUR. No
evidence comparing Memokath-051 to nephrostomy was
identified; hence a comparison of clinical and cost-effec-
tiveness was not possible.
3.4 Outcomes
Ten outcomes were specified in the scope [9]. The com-
pany presented data in relation to all of the outcomes
reported in the identified studies rather than those relevant
to the decision problem. The company did not attempt to
synthesise the outcomes reported across the trials. The
EAC reported on all the outcomes, including those relating
to complications, using the results from clinical studies
judged to have acceptable levels of external validity. In the
economic submission, the company addressed 3 outcomes,
namely the number and rate of replacement stents, the
length of time the stent remains in situ and the number and
rate of repeat procedures. The EAC included more out-
comes in its economic model.
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4 Review of Clinical and Economic Evidence
Section 4.1 summarises the clinical evidence submitted,
the EAC’s critique and the EAC’s additional work. Sec-
tion 4.2 provides the same detail for the economic
evidence.
4.1 Clinical Effectiveness Evidence
4.1.1 Company’s Review of Clinical Effectiveness
Evidence
The company searched for clinical evidence relating to the
decision problem and identified 23 papers for full-text
review, of which six publications describing five studies
were included in the submission. One of these, a non-
randomised, open-label study comparing Memokath-051
with double-J stents was reported as a clinical trial record
only [19]. Two were single-arm, observational studies
[2, 20, 21], one of which was reported in two publications
[2, 21]. A further observational study investigating Mem-
okath-051 identified by the company [22] could not be
found by the EAC. The final included paper reported on a
comparative study of Memokath-051 versus double-J stents
[7]. However, the company reviewed a different paper
reporting only data from the subgroup of patients that
received Memokath-051 from this study [23].
The company only partially completed the results
table for each included study and did not attempt to syn-
thesise the outcomes reported across the trials.
4.1.2 Critique of Clinical Effectiveness Evidence
The EAC planned to critique the company’s literature
search, evidence selection and quality assessment of
included studies. However, the description of the search
methodology was limited and not sufficient to accurately
replicate or evaluate the company’s search. Further, the
company’s selection criteria were not deemed appropriate
to identify all the studies relevant to the scope. Therefore,
the EAC undertook a de novo literature search and revised
the selection criteria to identify relevant clinical evidence
on Memokath-051. The EAC’s search strategies are
described in the EAC’s assessment report [4].
The EAC identified 1274 unique records, which were
assessed by two reviewers (Fig. 1). Due to the number of
studies meeting the EAC’s selection criteria, single-arm
studies reported in abstracts only (i.e. no full text available)
were excluded. Abstracts reporting comparative studies
were eligible for inclusion due to the paucity of published
comparative evidence. Sixteen studies, reported in 22
publications, were eligible for inclusion in the review.
These included all but one of the studies included in the
company’s review. However, an updated version of the
same study was identified by the EAC [24] and included in
its review. The EAC identified six comparative studies (of
which two were reported as full-text publications [7, 25],
three were conference abstracts [26–28] and one was pre-
sented in a clinical trial record and an abstract [17, 19]) and
ten single-arm, observational studies (each published as
full text) [16, 20, 21, 24, 29–34].
The comparative studies deemed eligible for inclusion
by the EAC are summarised in Table 1, and the single-arm
studies are summarised in the supplementary table (see the
electronic supplementary material).
The EAC critically appraised the internal and external
validity of three comparative studies [7, 19, 25] and ten
single-arm studies [16, 20, 21, 24, 29–34] (abstracts could
not be critically appraised due to insufficient information).
Two comparative studies provided acceptable levels of
internal validity [7, 25], whilst one study was considered to
have low internal validity [19]. All of the comparative
studies provided acceptable levels of external validity and,
therefore, were considered applicable to the scope and
acceptable in terms of generalisability [7, 19, 25]. The
single-arm studies generally had low levels of internal
validity; however, their external validity was enhanced by
the fact they were observational studies and, therefore, may
reflect clinical practice better than a strictly protocol-driven
trial. Two single-arm studies [16, 31] did not provide
acceptable levels of internal or external validity and were
excluded from further consideration.
Reporting on the outcomes was generally poor across
all the included studies. The most common outcomes
reported were clinical success and rates of migration.
Clinical success, however, was not consistently defined
across the studies, which meant statistical pooling could
not be conducted. In the comparative studies, Memokath-
051 had a lower clinical success rate than Allium stents
(81 vs 100%) [27], UVENTA (43 vs 82%, p = 0.31) [25]
and IUR (35 vs 89%) [26], but was comparable with
double-J stents (100% success rate in both arms) [17] and
Resonance stents (82 and 86% for Memokath-051 and
Resonance stents, respectively) [28]. Only one study
reported details of statistical significance [25] and found
that the difference observed between UVENTA and
Memokath-051 was not statistically significant [25]. Five
comparative studies reported on stent migration, and in all
cases, migration was more common for Memokath-051
than the comparator [7, 25–27]. Memokath-051 is judged
acceptable to patients, and evidence from a well con-
ducted study with acceptable external validity supports
improved quality of life [7]. The results extracted by the
EAC are presented in Table 2.
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The EAC identified significant limitations across the
methodology and results of the company’s review of the
clinical evidence. The company included only six publi-
cations [2, 19–23], which reported on five studies, whilst
the EAC identified 22 publications [7, 16, 19–21, 24–34],
which reported on 16 studies, through its de novo searches.
Overall, the entirety of the low-quality evidence suggests
Memokath-051 has similar success rates compared with
double-J stents and Resonance stents, but worse outcomes
than the other devices. The most commonly reported
adverse event associated with Memokath-051 was stent
migration, which occurred more frequently in Memokath-
051 than in any of the comparators assessed.
4.2 Economic Evidence
4.2.1 Company’s Economic Submission
The company conducted a limited search for economic
evidence, and of the 54 unique records identified, three
studies were included in the company’s economic review
[20, 22, 35]. Each compared Memokath-051 with double-J
stents, but no results were reported by the company. The
EAC judged one study to be poorly conducted and reported
[36] and the second difficult to appraise because it was
published as an abstract only [37]. The final study was an
unpublished cost-minimisation analysis reported by an
Fig. 1 EAC’s PRISMA diagram. EAC External Assessment Centre
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English NHS hospital (Aintree University Hospital) and
thus was also difficult to appraise [35]. The company used
data from this study within its submission.
The company submitted a de novo cost model (or cost
calculator), comparing Memokath-051 with double-J stents
over a time horizon of 2.5 years, developed in Microsoft
Excel. For both technologies, the cost of insertion (in-
cluding the cost of theatre staff, consumables and the
theatre tariff) and the cost of follow-up visits were inclu-
ded. Complications associated with the device were only
included in the Memokath-051 arm and were encapsulated
within a risk factor for an unplanned stent exchange. This
was applied by multiplying the sum of the pathway-related
costs per patient over the 2.5-year time horizon by 25%.
This cost premium was added to the total cost over
2.5 years for treatment with Memokath-051. The Memo-
kath-051 stent did not have a planned replacement within
the 2.5-year time horizon. Replacement of double-J stents
occurred every 6 months and so the cost of the initial
double-J stent insertion and four planned stent exchanges,
as well as the patient follow-up appointments, were sum-
med to generate the total per patient cost over 2.5 years for
double-J stents. Figure 2 is a diagram of the company’s
model (developed by the EAC).
To populate its economic analysis, the company pri-
marily utilised data from a cost-minimisation analysis
conducted by Aintree University Hospital [35]. This
reported on the costs associated with the use of Memokath-
051 compared with double-J stents for 24 patients requiring
32 stents for long-term stenting of malignant and benign
strictures. The risk factor for an unplanned stent exchange
in the Memokath-051 arm was justified by the company
with reference to a clinical study [24], but a clear expla-
nation of where this value was derived from was not pro-
vided. The perspective adopted was not reported by the
company, but given that all costs modelled were sourced
from a single English hospital, an NHS hospital perspective
was taken. All model input parameters are shown in
Table 3. Further details are given in the EAC report [5].
Base case results from the company’s model estimated
that Memokath-051 generated cost savings of £4156 per
patient compared with double-J stents. This was based on
costs of £4726 per patient treated with Memokath-051 and
£8882 per patient receiving double-J stent. No sensitivity
or subgroup analyses were conducted by the company.
4.2.2 Critique of Economic Evidence
The EAC did not evaluate or re-run the company’s eco-
nomic searches given the limited description of the search,
but conducted its own literature search. The EAC judged
two of the company’s included studies to be out of scope
[20, 22], but agreed that inclusion of the cost-minimisation
analysis [35] was appropriate. Two further studies were
included by the EAC [36, 37]. All three included studies
were cost-consequence analyses comparing Memokath-051
with double-J stents, with only the analysis conducted by
Aintree University Hospital representative of NHS practice
[35]. This reported cost savings of £27 in the first year and
£4095 in the second year when using Memokath-051
compared to double-J stents.
The EAC judged it appropriate for the company to
develop its own de novo cost model given the limited
published evidence. Whilst the model captured the key
differences between the two stent types, namely the cost of
insertion, planned replacements with double-J stents and
unplanned replacements with Memokath-051, the model
was not executable, reported results based on an unpub-
lished analysis [35], and took a hospital perspective. This
deviates from the scope, which requires that an NHS and
Personal Social Services (PSS) perspective is taken. Fur-
ther, the EAC identified that data were available for other
metallic stents and surgical procedures used within the
NHS, enabling cost comparisons with Memokath-051 to be
undertaken. However, there were insufficient data on
nephrostomy.
The EAC replicated the company’s calculations and
identified no calculation errors. The Drummond checklist
was used to appraise the model [38], identifying the fol-
lowing issues:
• A time horizon of 2.5 years was used, but limited data
were reported in the comparative trials in relation to the
length of time in situ, and these data were driven by the
follow-up of the trials.
• The model assumes that all patients remain alive at
2.5 years following insertion, which may not be the
case for patients with shorter life expectancy.
• Adverse events that do not result in the removal of the
stent, such as urinary tract infection (UTI), were
excluded. The clinical review identified that some
patients experienced these adverse events after stenting
[19, 26, 32, 34].
• The company’s model did not capture benefits relating
to reduced pain and improved quality of life with
Memokath-051 [7].
• Discounting was not applied to costs that occur beyond
year 1, as required by NICE [39].
• Sensitivity analyses were omitted.
All model inputs used by the company were validated by
the EAC, with some issues identified. A key clinical
parameter used by the company in the Memokath-051 arm
was to assume 25% of patients require a stent replace-
ment over 2.5 years (equivalent to 0.89% per month).
This value was not supported by the clinical evidence,
where a value of 1.4% per month was estimated
E. Eaton Turner et al.
[20, 21, 24, 25, 29, 30, 33]. Regarding resource use, whilst
expert advice verified that the composition of theatre staff
included was appropriate, the procedure time for insertion
and replacement surgeries was overestimated at 4 h. Pro-
cedure times for the insertion of Memokath-051 and dou-
ble-J stents of 45 and 22.5 min, respectively, were deemed
more appropriate by the EAC based on expert advice.
Theatre staff costs were also included as salary costs, hence
inappropriately omitting other salary-related costs (national
insurance and superannuation). The company also included
a surgery tariff in their model, which was inappropriate
given the perspective adopted. The amendments to the
Fig. 2 Economic model schematic developed by the company. Asterisk refers to multipled by
The Memokath-051 Stent: A NICE Medical Technology Guidance
company’s input values resulted in the EAC using a total
cost of insertion for Memokath-051 of £3010 instead of the
company’s value of £3068 and a cost of £786 for double-J
stents as opposed to the company’s estimate of £1676.
4.2.3 Additional Work Undertaken by EAC Relating
to Economic Evidence
Given the limitations described in Sect. 4.2.2, the EAC
adapted the company’s model. The patients and
Table 3 Model input parameters used in company’s model
Variable Value
per
patient
Source EAC critique
Theatre staff
costs:
Memokath-051
£1160 [35]
Included: anaesthetist, surgeon, band 6 and band 5
scrub, band 5 anaesthetist, band 2 circulating, band 2
porter, band 6 and band 5 recovery
Duration of procedure: procedure time of 4 h and a
theatre time (all staff present apart from the surgeon)
of 4.5 h. The EAC judged this to be too long based
upon information provided by the company and
experts
Recovery staff: Cost of a band 5 and band 6 recovery
staff included appropriately given that no additional
hospital stay was included following insertion
Staff costs: Staff costs per hour did not include national
insurance and superannuation costs. These are directly
related to earnings and should be included
Theatre staff
costs: double-J
stent
£1160 [35]
Included: anaesthetist, surgeon, band 6 and band 5
scrub, band 5 anaesthetist, band 2 circulating, band 2
porter, band 6 and band 5 recovery
Duration of procedure: as above
Recovery staff: as above
Staff costs: as above
Theatre
consumable
costs:
Memokath-051
£1874 [35]
Included: device, cystoscopy pack, instilagel, 20-ml
syringe, sensor guide wire, passport, jug, pink needle,
green needle
The company’s consumable cost includes a device cost
of £1630. This is lower than the current list price of
£1690 reported in the company’s submission
Theatre
consumable
costs: double-J
stent
£109 [35]
Included: device, cystoscopy pack, instilagel, 20-ml
syringe, sensor guide wire
The EAC deems this value appropriate based upon the
AUH data [35]
Procedure
code/surgery
tariff:
Memokath-051
£34 [35] The EAC judges the inclusion of a tariff cost is
inappropriate for analysis from the NHS and PSS
perspective and excluded this parameter from its
analysis
Procedure
code/surgery
tariff: double-J
stent
£407 [35] As above
6-month follow-
up costs:
Memokath-051
£143 [35]
Included: x-ray abdomen, nuclear medicine renogram
and 2 outpatient appointments over 1 year. 1 year cost
divided by 2 to estimate the 6 month cost
The EAC deems this value appropriate based upon the
AUH data. However, using national sources for unit
costs would increase the cost [40]
6-month follow-
up costs:
double-J stent
£100 No source provided It is unclear how this cost was derived and is not
included within the AUH data, thus is deemed
inappropriate
Risk of unplanned
exchange:
Memokath-051
£945 Calculated as 25% of the undiscounted pathway-related
cost for 2.5 years
The EAC judges that this cost has been applied
incorrectly given that it was applied to the total per
patient cost over 2.5 years as opposed to the insertion
cost only
Risk of unplanned
exchange:
double-J stent
£0 Zero as no risk factor for complications Given that double-J stents undergo planned
replacement, this is considered appropriate and is in
line with clinical evidence [7]
AUH Aintree University Hospital, EAC External Assessment Centre, NHS National Health Service, PSS Personal Social Services
E. Eaton Turner et al.
interventions included in the EAC’s model were aligned
with the scope, except the exclusion of nephrostomy as a
comparator. Costs were modelled over a 5-year time frame,
reflecting the indwelling duration for Memokath-051, after
which planned replacement is required according to the
company. The EAC’s model was updated such that time
was explicitly modelled by month, allowing the break-even
point between Memokath-051 and its comparators to be
determined. However, the assumption of patients surviving
for the duration of the model was retained.
To determine the pathway costs with Memokath-051,
double-J stents and other metallic stents, the EAC included
the costs of:
• Initial insertion for all patients (including the costs of
the device, consumables, staff, theatre and immediate
follow-up).
• On-going follow-up for all patients.
• Unplanned replacement costs where necessitated by an
adverse event (including the cost of consumables, staff,
theatre and follow-up).
• UTI costs for those experiencing a UTI (general
practitioner visit and antibiotics).
• Planned replacement for all patients based upon the
instructions for use for each comparator device.
Given that the monthly risk of unplanned replacements
was derived from the clinical studies and that the follow-up
of these studies was shorter than the time horizon of the
model, extrapolation was required. Three extrapolation
methods were considered: (1) a uniform monthly risk of
unplanned replacement was applied for the 5-year horizon
of the model; (2) the monthly risk of unplanned replace-
ment was applied for 2 years followed by no risk of
unplanned replacement; (3) the monthly risk of unplanned
replacement was applied for 2 years followed by a reduced
risk of unplanned replacement. The latter two scenarios
attempted to capture scenarios in which unplanned
replacements occur early in a stent’s lifespan, rather than
spontaneously occurring after the stent has been in situ
with no complications for 2 years.
The pathway associated with reconstructive surgery
(conservatively assumed to be successful in all cases) was
costed. Whilst some patients may require additional sur-
gery, the magnitude of this could not be identified from
either the literature or the experts and so was not modelled.
All patients were assumed to require follow-up in the first
month post-surgery. Experts advised that most patients
would not have continued follow-up thereafter. Figure 3
gives a schematic of the EAC’s model.
Table 4 summarises the model inputs included by the
EAC.
The EAC generated results based on various scenarios
relating to unplanned stent replacement for all stents. In all
scenarios, Memokath-051 was cost saving compared with
double-J stents within a 5-year time horizon. The break-
even point between Memokath-051 and double-J stents was
30 months in all scenarios. Memokath-051 improved
patient-related quality of life compared with double-J
Fig. 3 Economic model schematic developed by the EAC. EAC External Assessment Centre
The Memokath-051 Stent: A NICE Medical Technology Guidance
T
a
b
le
4
M
o
d
el
in
p
u
t
p
ar
am
et
er
s
u
se
d
in
E
A
C
’s
m
o
d
el
P
ar
am
et
er
M
em
o
k
at
h
-0
5
1
D
o
u
b
le
-J
st
en
t
U
V
E
N
T
A
A
ll
iu
m
R
es
o
n
an
ce
R
ec
o
n
st
ru
ct
iv
e
su
rg
er
y
L
en
g
th
o
f
ti
m
e
in
si
tu
(n
o
co
m
p
li
ca
ti
o
n
s)
C
o
m
p
an
y
=
3
0
m
o
n
th
s
C
o
m
p
an
y
=
6
m
o
n
th
s
C
o
m
p
an
y
=
N
A
C
o
m
p
an
y
=
N
A
C
o
m
p
an
y
=
N
A
C
o
m
p
an
y
=
N
A
E
A
C
=
6
0
m
o
n
th
s
E
A
C
=
6
m
o
n
th
s
E
A
C
=
1
8
m
o
n
th
s
E
A
C
=
3
6
m
o
n
th
s
E
A
C
=
1
2
m
o
n
th
s
E
A
C
=
N
A
M
o
n
th
ly
ri
sk
fo
r
u
n
p
la
n
n
ed
st
en
t
re
m
o
v
al
an
d
re
p
la
ce
m
en
t
C
o
m
p
an
y
=
0
.9
5
%
(r
ep
o
rt
ed
as
2
5
%
o
v
er
3
0
m
o
n
th
s)
0
%
N
A
N
A
N
A
N
A
E
A
C
=
1
.4
%
(4
.4
1
%
v
s
U
V
E
N
T
A
)
0
%
0
.4
9
%
0
.4
9
%
1
.4
%
N
A
M
o
n
th
ly
ri
sk
o
f
U
T
I
C
o
m
p
an
y
=
N
A
N
A
N
A
N
A
N
A
N
A
E
A
C
=
0
.4
2
%
(1
.2
5
%
v
s
su
rg
er
y
)
0
.4
2
%
0
.4
2
%
0
.4
2
%
0
.4
2
%
0
.1
7
%
T
o
ta
l
co
st
o
f
in
se
rt
io
n
C
o
m
p
an
y
=
£
3
0
6
8
£
1
6
7
6
N
A
N
A
N
A
N
A
E
A
C
=
£
3
0
1
0
£
7
8
6
£
2
7
3
6
£
2
9
3
6
£
2
1
4
8
£
7
4
1
4
(i
n
cl
u
d
es
al
l
fo
ll
o
w
-u
p
co
st
s)
M
o
n
th
ly
fo
ll
o
w
-u
p
co
st
C
o
m
p
an
y
=
£
2
3
.7
5
£
1
6
.6
7
N
A
N
A
N
A
N
A
E
A
C
=
£
4
2
.5
0
£
0
£
4
2
.5
0
£
4
2
.5
0
£
2
1
.2
5
N
A
T
o
ta
l
co
st
o
f
re
p
la
ce
m
en
t
C
o
m
p
an
y
=
£
3
7
8
1
£
1
6
7
6
N
A
N
A
N
A
N
A
E
A
C
=
£
3
3
4
7
£
1
0
5
2
£
3
1
5
7
£
3
3
5
7
£
2
5
6
9
N
A
C
o
st
o
f
U
T
I
C
o
m
p
an
y
=
N
A
E
A
C
=
£
3
7
.3
2
E
A
C
E
x
te
rn
al
A
ss
es
sm
en
t
C
en
tr
e,
N
A
n
o
t
ap
p
li
ca
b
le
,
U
T
I
u
ri
n
ar
y
tr
ac
t
in
fe
ct
io
n
E. Eaton Turner et al.
stents. The EAC’s estimated savings per patient with
Memokath-051 ranged from £1619 to £3095, depending on
the scenario, somewhat lower than the company’s estimate
(£4156).
When comparing Memokath-051 to reconstructive sur-
gery, the incremental cost per patient after 5 years ranged
from £467 to - £1009, depending upon the assumptions
made around the extrapolation of unplanned replacement
of Memokath-051 stents. Compared with surgery, Memo-
kath-051 was cost saving up to 53 months, suggesting that
if costs are the only criterion then Memokath-051 is the
optimal choice for patients with a lower life expectancy.
Reconstructive surgery would be the preferred option for
patients able to tolerate it and anticipated to live longer
than 4.5 years.
The key factor in comparisons between Memokath-051
and other metallic stents is the planned stent replacement
for each comparator. Based on the EAC’s analysis, Mem-
okath-051 is judged to be cost neutral compared with
UVENTA and Allium in the worst case (i.e. uniform rate of
replacement), but may generate cost savings with more
positive assumptions (i.e. no unplanned replacements after
2 years). Compared with Resonance, Memokath-051 was
cost saving after 12 months. The results for both Allium
and Resonance should be interpreted with caution as they
are based on assumptions and not comparative clinical
data.
The EAC identified a plausible range for each input
parameter and varied the parameter within this range.
When comparing Memokath-051 to double-J stents, for the
scenario with a constant risk of unplanned replacement
over 5 years (most conservative scenario), the results were
sensitive to the procedure costs of replacing double-J stents
and the risk of unplanned replacements with Memokath-
051. Where the replacement procedure cost for double-J
stents was below £860 (consistent with a procedure time of
38 min or less) or the monthly risk of unplanned replace-
ments with Memokath-051 was above 3.6% per month,
Memokath-051 was cost incurring. A monthly risk of
replacement of above 4% was only reported in one non-UK
study [25], whilst the remaining studies reported monthly
risks of replacement of 1.6% or below. In all univariate
analyses, break-even occurred by month 42, except for
those analyses varying the procedure costs of replacing
double-J stents and the risk of unplanned replacements
with Memokath-051.
Compared with the other metallic stents, results were
most sensitive to the risk of unplanned replacement with
Memokath-051 stents. Model results were highly sensitive
to many input values when Memokath-051 was compared
with surgery, particularly in the worst-case scenario.
5 NICE Guidance
5.1 Provisional Recommendations
The evidence submitted by the company and the EAC’s
critique of this evidence was presented to the MTAC, who
provided draft recommendations relating to Memokath-051
following their meeting in September 2017. These are
summarised as follows:
• The case for adopting Memokath-051 stents for the
treatment of ureteric obstruction is partially supported
by the evidence. There is limited clinical, procedural
and outcomes evidence, and clinicians using ureteric
stents including Memokath-051 stents should therefore
submit data to a national registry.
• Memokath-051 stents, when implanted by trained and
experienced surgeons and in appropriate patients, are
associated with equivalent success rates to double-J
stents and a better patient experience.
• The cost consequences of adopting the Memokath-051
stent in current pathways are uncertain. However, when
used in specific populations and by experts trained in its
use, it may be cost neutral or cost saving compared with
standard treatment because of reduced need for repeat
procedures.
5.2 Consultation Response
During the consultation, NICE received 19 consultation
comments from seven consultees. The NICE guidance was
updated to address a number of these comments. The
recommendations were updated in response to a comment
regarding a national registry and to provide clarification on
patient choice. Although the committee considered that
data collection was still needed to better understand the
benefits of Memokath-051, it decided to remove a specific
recommendation about the type of data collection to allow
for further discussion. Further changes were made to better
reflect that patients may choose to decline particular
treatments. These changes were augmented with additional
explanatory text in the patient selection with benign ure-
teric obstruction and future data collection sections.
6 Key Challenges and Learning Points
There were some key challenges faced by both the EAC
and the company during the evaluation. The analysis was
not able to fully address the decision problem given that
data on nephrostomy and all of the subgroups defined in the
scope were not available. The available evidence base
The Memokath-051 Stent: A NICE Medical Technology Guidance
comprised mainly small, poorly reported, observational
studies. Although the observational nature of the studies
may be more reflective of real life, due to the heterogeneity
across them it is difficult to draw reliable conclusions. The
poor quality of data increased reliance on expert advice
thus increasing the demands of the project given the
specified timelines. Further, there were multiple compara-
tors included in the scope, which increased the demand for
data. The comparative evidence for Memokath-051 versus
Resonance and Allium stents was poor, meaning that there
is even greater uncertainty around the results. Therefore, all
conclusions are uncertain and could alter with new evi-
dence. A large, well conducted randomised controlled trial
or prospective comparative study would improve the evi-
dence base and provide more reliable estimates of the
efficacy and safety of these devices.
There were also multiple types of reconstructive surgery
available to these patients, which were not modelled
explicitly. The inclusion of reconstructive surgery as a
comparator treatment has some caveats associated with it
as highlighted by the clinical experts. The major caveat is
that reconstructive surgery aims to be curative; thus it
should always be considered for patients with a longer life
expectancy who are able to tolerate major surgery.
It was clear during the analysis that the patient popu-
lation was heterogeneous, with the patient’s life expectancy
being an important factor. To account for this, the EAC
identified the break-even point as the month up to which
Memokath-051 would generate cost savings for each
comparative analysis.
An additional challenge for this analysis was the
uncertainty associated with the maximum duration of stent
indwelling. This issue arose given that the length of the
follow-up period of the clinical trials was shorter than the
indicated lifetime for stent replacement. The EAC used
four methods of extrapolation to account for different
possible scenarios. When generating the results for Mem-
okath-051 compared with each comparator, there was no
clear base case and instead the results were reported for
each of the different scenarios.
Lastly, a particular challenge faced by the EAC was the
poor quality of the company’s submission. This resulted in a
significant amount of additional work being conducted by
the EAC.NICE can offer assistance to companies prior to the
assessment process, and utilisation of this by the company
could have led to a more efficient assessment of the device.
7 Conclusion
The MTEP evaluation process was followed for the
development of medical technologies guidance on Memo-
kath-051. This included a submission of clinical and
economic evidence by the company, critical appraisal of
this evidence by the EAC, extensive additional work by the
EAC to capture all available evidence relating to the
decision problem and to develop an executable economic
model to help inform the decision makers’ recommenda-
tions and capture the uncertainty of the decision, drafting
of recommendations by the MTAC, and a subsequent
public consultation. Following this process, the MTAC
judged that the evidence demonstrated sufficient potential
benefits of Memokath-051 to patients and the NHS to allow
partially supportive recommendations to be made for the
device.
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